Randomized controlled trialHuman
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
JAMA, 2014 Jul 23-30. Stanley TL, Feldpausch MN, Oh J and 4 others.
Study type
Randomized controlled trial
Subjects
Human participants (PubMed MeSH: Humans)
Journal
JAMA
Published
2014 Jul 23-30
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
Abdominal FatAdiposityAdultDouble-Blind MethodFatty LiverFemaleGrowth Hormone-Releasing HormoneHIV InfectionsHumansIntra-Abdominal FatLiverMale
Other papers on Tesamorelin
Randomized controlled trial · 2019
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
Randomized controlled trial · 2010Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page